Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine dose-ranging perioperative study in elderly patients undergoing minimally invasive esophagectomy
ChiCTR2500103300Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in esophageal cancer (4 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Serum concentrations of HS, ET-1, TM, CC-16 and SP-D. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2500103300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103300.